Also known as: Exscientia
Exscientia is a technology-driven drug design and development company that uses artificial intelligence to create more effective medicines faster. The company combines precision design, automation, and experimentation to invent and develop drugs more efficiently.
AI is transforming drug discovery across target ID, molecule design and trial optimization. Milestones include regulatory qualification of digital-twin controls and positive Phase 2a data, though 90-95% of candidates still fail.
Drug R&D platform markets are projected to grow through 2031, driven by AI and computational chemistry. Innovation and simulation platforms accelerate drug discovery across pharmaceutical, chemical, and medical industries.
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
Juvenescence, a clinical-stage AI-enabled biotech company, has appointed Eileen Jennings-Brown as Chief Technology Officer and established new research offices at Masdar City in Abu Dhabi to advance its longevity therapeutics pipeline.
